Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity

Papadavid E, Bagot M, Hodak E, Guenova E, Guiron R, Dimitriou F, Cozzio A, Vico C, Ortiz-Romero P, Quaglino P, Engelina S, Porkert S, Jonak C, Dalamaga M, Iliakis T, Nikolaou V, Pappa V, Kapniari E, Scarisbrick J. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity. Br J Dermatol 2021; 185:1035-1044.